Patent application number | Description | Published |
20110203261 | Snapper Valve for Hot End Systems with Burners - A system for controlling the temperature of an exhaust stream includes a main exhaust passageway adapted to receive the exhaust stream from an engine. A bypass passage includes an inlet and an outlet in communication with the main exhaust passageway. The outlet is located downstream from the inlet. A burner is positioned within the bypass passage for treating the exhaust passing through the bypass passage. A valve is positioned within the main exhaust passageway downstream from the inlet and upstream from the outlet. The valve is operable to vary the exhaust flow through the burner. A controller selectively operates the burner to maintain a desired exhaust temperature downstream of the outlet. | 08-25-2011 |
20130343959 | COMMON RAIL REDUCTANT INJECTION SYSTEM - An exhaust system including a selective catalytic reduction (SCR) component and an oxidation catalyst component. The exhaust system also includes an exhaust treatment fluid injection system for dispersing an exhaust treatment fluid into an exhaust stream at a location adjacent either the SCR component or the oxidation catalyst component, wherein the exhaust treatment fluid injection device includes a common rail that provides the exhaust treatment fluid under pressure to a plurality of injectors that dose the exhaust treatment fluid into the exhaust stream. The exhaust treatment fluid injection device also includes a return rail for returning unused exhaust treatment fluid to the fluid source. | 12-26-2013 |
20140114619 | Burner Outlet Designs for Locomotive Burner Integration - A method of determining an optimized position for a burner in an exhaust aftertreatment system includes estimating temperature distributions across faces of exhaust treatment devices positioned within parallel paths based on an initial burner position upstream of the parallel paths. A temperature distribution across the faces of the exhaust treatment device is again estimated based on a changed burner position. A difference between the estimates is determined. The changing, estimating and determining steps are repeated to correlate the burner position with a temperature variance across the faces. An optimized burner position is determined based on minimizing the temperature variance across the faces of the exhaust treatment devices. | 04-24-2014 |
20140150411 | REDUCTANT INJECTION CONTROL SYSTEM - An exhaust system including a plurality of exhaust treatment devices, plurality of injectors for dosing an exhaust treatment fluid into an exhaust stream, and a controller for controlling each of the plurality of injectors. The controller actively controls an amount of exhaust treatment fluid dosed into the exhaust stream by each of the plurality of injectors based on at least one of an exhaust flow rate and a temperature of the exhaust stream. | 06-05-2014 |
Patent application number | Description | Published |
20100122571 | METHOD AND SYSTEM FOR ESTIMATING ENGINE OIL LIFE BASED ON VISCOSITY - A method and control module for indicating engine oil life includes a viscosity determination module determining a viscosity of the engine oil based on an engine oil pressure and engine oil temperature. The control system further includes a comparison module comparing the viscosity of the engine oil to a threshold and generating a warning signal in response to comparing the viscosity. | 05-20-2010 |
20120118021 | KNITTING NEEDLE AND CROCHET HOOK ASSEMBLY - A yarn needle assembly may include a first needle member, a second needle member and a cable. The cable may have a first end coupled to an end of the first needle member and a second end coupled to an end of the second needle member. The cable may include a metal cable formed from a plurality of braided metal strands with a nylon coating surrounding the metal cable. The relationship between an overall diameter (D | 05-17-2012 |
20130073178 | DIAGNOSTIC SYSTEM AND METHOD FOR A VARIABLE VALVE LIFT MECHANISM - A system according to the principles of the present disclosure includes a timing control module and a diagnostic module. The timing control module controls engine valve timing by sending fluid to an advancing chamber of a cam phaser to adjust the cam phaser to an advanced position and by sending fluid to a retarding chamber of the cam phaser to adjust the cam phaser to a retarded position. The diagnostic module identifies a fault in a variable valve lift (VVL) mechanism based on a first difference between an advancing pressure of the advancing chamber and a retarding pressure of the retarding chamber. | 03-21-2013 |
20130233271 | OIL SQUIRTER WITH DAMPING VENT - An oil squirter for an engine includes a piston-type valve having a damping vent configured to damp oscillations of the valve piston during opening and closing. The valve piston may be spring biased and the valve may opened by oil pressure exerted on the piston at or above a cracking pressure. The damping vent controls displacement of the valve piston by creating delta pressure in oil contained in a piston chamber in opposition to axial piston movement during opening and closing of the valve, to stabilize the axial movement of the piston thereby damping valve oscillation during valve opening and closing. The damping vent operates to increase cracking stability and eliminate cyclic contact of the valve piston and valve seat to prevent noise, wear, binding, and oil system pressure fluctuations due to squirter valve instability. | 09-12-2013 |
Patent application number | Description | Published |
20090325868 | Materials And Methods For FOXP3 Tumor Suppression - Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such cells, and methods of inducing apoptosis of these cells are also provided herein. These methods comprise contacting the cell with a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Further provided herein are diagnostic methods, comprising comparing the expression or structure of a FOXP3 protein or FOXP3 gene in a test sample to that of a normal or prior sample. A method of screening a test compound for anti-cancer activity comprising administering to cells the test compound and measuring FOXP3 protein or FOXP3 gene expression is moreover provided herein. | 12-31-2009 |
20110064746 | TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD24-HMGB1-SIGLEC10 AXIS - The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient. | 03-17-2011 |
20120201819 | TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD-24-HMGB1-SIGLEC10 AXIS - The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient. | 08-09-2012 |
20120264697 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS - The present invention relates to treating a hematologic cancer using a Hypoxia- Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor. | 10-18-2012 |
20120294884 | METHODS OF BLOCKING TISSUE DESTRUCTION BY AUTOREACTIVE T CELLS - Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided. In one embodiment, the method comprises administering a purified CD24 polypeptide, a fusion protein comprising such polypeptide, or a biologically active fragment of such polypeptide to a mammalian subject who is suspected of having or predisposed to having an autoimmune disease. In another embodiment, anti-CD24 antibody or anti-CD24 Fab fragments are administered to the subject. In another embodiment, the method comprises administering a CD24 antisense molecule, an expression vector encoding a CD24 antisense molecule, CD24 dsRNAi, or an expression vector encoding CD24 dsRNAi to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells. | 11-22-2012 |
20130136739 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 05-30-2013 |
20130231464 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 09-05-2013 |
20130296249 | METHODS OF BLOCKING TISSUE DESTRUCTION BY AUTOREACTIVE T CELLS - Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided. In one embodiment, the method comprises administering a purified CD24 polypeptide, a fusion protein comprising such polypeptide, or a biologically active fragment of such polypeptide to a mammalian subject who is suspected of having or predisposed to having an autoimmune disease. In another embodiment, anti-CD24 antibody or anti-CD24 Fab fragments are administered to the subject. In another embodiment, the method comprises administering a CD24 antisense molecule, an expression vector encoding a CD24 antisense molecule, CD24 dsRNAi, or an expression vector encoding CD24 dsRNAi to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells. | 11-07-2013 |
20140107322 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 04-17-2014 |
20150239953 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 08-27-2015 |
Patent application number | Description | Published |
20080236539 | TRANSMISSION CLUTCH PRESSURE CONTROLS VIA PILOT PRESSURE FEEDBACK - A transmission clutch pressure control apparatus is suitable for a configuration that includes a pilot valve and a pressure regulating valve working in tandem. The pilot valve produces a pilot pressure that varies in accordance with a pilot valve drive signal. The pressure regulating valve provides fluid to a clutch at an output clutch pressure that is in turn variable based on the pilot pressure. The apparatus includes a pilot pressure sensor in fluid communication with the pilot valve output and generates a pilot pressure signal. The apparatus also includes a control arrangement having a pilot valve pressure estimation block configured to produce a pilot pressure command in response to a clutch pressure command. The estimation block is configured to reflect the relationship between the clutch pressure and the pilot pressure. The control arrangement also includes a summer that produces an error signal based on the difference between the commanded and sensed pilot pressure. The control arrangement also includes additional control blocks implementing a control strategy that ultimately develops and output the pilot valve drive signal all based on the pilot pressure command and the pilot pressure error signal. | 10-02-2008 |
20090012772 | METHOD FOR GENERATING AN ELECTRO-HYDRAULIC MODEL FOR CONTROL DESIGN - The dynamic response characteristics of an electro-hydraulic (EH) physical plant is represented by a model. The model includes a series of second order transfer functions, one for each operating point, of the EH physical plant. Command pressure, overshoot, rise time, damping coefficient, natural frequency and gain parameters are determined in developing each transfer function. The model can be used to advance the time in which the design and development of a control system for the EH physical plant can begin. | 01-08-2009 |
20090222179 | DYNAMIC LEARNING OF SOLENOID P-I CURVES FOR CLOSED LOOP PRESSURE CONTROLS - In a pressure control system having a solenoid-operated fluid valve that has an output hydraulic pressure which varies in accordance with a solenoid input signal, a dynamic learning block is configured to adjust the initial, default values for control points stored in a pressure-current (P-I) data table based on observed (measured) operating points that reflect the solenoid's actual transfer characteristic. A feed forward control block is configured to generate the solenoid input signal having a level based on the adjusted control points in the data table, which improves the accuracy of the solenoid input signal. An adjustment method uses a plurality of circular buffers each configured to store observed operating points falling within a respective range, and provides a mechanism to allow adjustment of the control points based on only partial data. | 09-03-2009 |
20090222180 | METHOD FOR REAL-TIME LEARNING OF ACTUATOR TRANSFER CHARACTERISTICS - In a pressure control system having a solenoid-operated fluid valve that has an output hydraulic pressure which varies in accordance with a solenoid input signal, a dynamic learning block is configured to adjust the initial, default values for control points stored in a pressure-current (P-I) data table based on observed (measured) operating points that reflect the solenoid's actual transfer characteristic. A feed forward control block is configured to generate the solenoid input signal having a level based on the adjusted control points in the data table, which improves the accuracy of the solenoid input signal. An adjustment method uses a plurality of circular buffers each configured to store observed operating points falling within a respective range, and provides a mechanism to allow adjustment of the control points based on only partial data. | 09-03-2009 |
20100137093 | Automatic Transmission with Closed Loop Pressure Electro-Hydraulic Control Module - An automatic transmission is disclosed that includes a clutch pressure control module housing having therein:
| 06-03-2010 |
Patent application number | Description | Published |
20110064746 | TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD24-HMGB1-SIGLEC10 AXIS - The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient. | 03-17-2011 |
20120201819 | TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD-24-HMGB1-SIGLEC10 AXIS - The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient. | 08-09-2012 |
20130136739 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 05-30-2013 |
20130231464 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 09-05-2013 |
20140107322 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 04-17-2014 |
20150239953 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 08-27-2015 |